Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06714955 · ClinicalTrials.gov registry record · Phase 1
Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BGM0504 Injection in Non-diabetic Overweight or Obese Adult Subjects
A Phase 1 study, sponsored by BrightGene Bio-Medical Technology Co..
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT06714955: Completed Phase 1 study, sponsored by BrightGene Bio-Medical Technology Co..
NCT06714955 is a Phase 1 study that has completed, run by BrightGene Bio-Medical Technology Co.. The registered enrollment target is 30 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (50% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06714955, a Phase 1 study, has completed, sponsored by BrightGene Bio-Medical Technology Co..
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
This is a Phase 1, double-blind, parallel-arm ,placebo-controlled study. The study will evaluate the pharmacokinetics (PK), pharmacodynamic (PD), safety and tolerability of BGM0504 following multiple subcutaneous (SC) administrations in non-diabetic overweight or obese adult subjects.
Primary Outcome
The relationship of each adverse event tothe investigational product was assessed by the investigator
Interventions
- DRUG Experimental: 10 mg BGM0504 10 milligrams (mg) BGM0504 administered subcutaneously (SC) once a week.
- DRUG Experimental: 15 mg BGM0504 15 mg BGM0504 administered SC once a week.
- DRUG Placebo Comparator: Placebo Placebo administered subcutaneously (SC) once a week.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2024-10-21 |
| Est. Completion | 2025-03-03 |
| Phase | Phase 1 |
What the finished NCT06714955 record still lists
NCT06714955 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (50% lower).
The record links to 0 conditions, and to 3 interventions - of which Experimental: 10 mg BGM0504 10 milligrams (mg) BGM0504 administered subcutaneously (SC) once a week. is the first listed.
NCT06714955 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06714955 about?
NCT06714955 is a clinical study titled "Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BGM0504 Injection in Non-diabetic Overweight or Obese Adult Subjects". This is a Phase 1, double-blind, parallel-arm ,placebo-controlled study. The study will evaluate the pharmacokinetics (PK), pharmacodynamic (PD), safety and tolerability of BGM0504 following multiple subcutaneous (SC) administrations in non-diabetic overweight or obese adult subjects.
What is the current status of trial NCT06714955?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2024-10-21. Estimated completion is 2025-03-03.
What interventions are being tested in trial NCT06714955?
The interventions under investigation include: Experimental: 10 mg BGM0504 10 milligrams (mg) BGM0504 administered subcutaneously (SC) once a week. (DRUG), Experimental: 15 mg BGM0504 15 mg BGM0504 administered SC once a week. (DRUG), Placebo Comparator: Placebo Placebo administered subcutaneously (SC) once a week. (DRUG).
Who is sponsoring clinical trial NCT06714955?
This trial is sponsored by BrightGene Bio-Medical Technology Co., which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06714955's enrollment target sits among peer trials
30 1332nd of 2000 higher than 561 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI